Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 18

Results For "FY"

2292 News Found

Indegene posts Q4 FY25 consolidated PAT at Rs. 117.6 Cr
News | April 29, 2025

Indegene posts Q4 FY25 consolidated PAT at Rs. 117.6 Cr

The company has posted net profit of Rs. 406.7 crores for the Financial Year ended March 31, 2025


Dr. Lal Path Labs posts Q4 FY25 consolidated PAT at Rs. 154.8 Cr
News | April 28, 2025

Dr. Lal Path Labs posts Q4 FY25 consolidated PAT at Rs. 154.8 Cr

The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025


Laurus Labs Q4 FY25 PAT up 208% to Rs. 234 Cr
News | April 24, 2025

Laurus Labs Q4 FY25 PAT up 208% to Rs. 234 Cr

The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25


Syngene International posts Q4 FY25 consolidated profit at Rs. 183.3 Cr
News | April 24, 2025

Syngene International posts Q4 FY25 consolidated profit at Rs. 183.3 Cr

Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time


Thyrocare Technologies Q4 FY25 consolidated PAT up at Rs. 21.70 Cr
News | April 24, 2025

Thyrocare Technologies Q4 FY25 consolidated PAT up at Rs. 21.70 Cr

For the financial year ended March 31, 2025, Thyrocare has reported total income of Rs.702.18 crores


Plex Research partners With Ginkgo Bioworks on AI powered drug discovery to identify novel disease mechanisms
News | April 07, 2025

Plex Research partners With Ginkgo Bioworks on AI powered drug discovery to identify novel disease mechanisms

Findings likely to generate hypotheses about potential new uses of drugs


Wanbury reports 88% drop in Q3 FY25 PAT
News | February 21, 2025

Wanbury reports 88% drop in Q3 FY25 PAT

Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25


Glenmark Pharma reports Q3 FY25 PAT at Rs. 348 Cr
News | February 17, 2025

Glenmark Pharma reports Q3 FY25 PAT at Rs. 348 Cr

Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY


IOL Chemicals and Pharmaceuticals reports Q3 FY25 revenue at Rs. 527.37 Cr
News | February 14, 2025

IOL Chemicals and Pharmaceuticals reports Q3 FY25 revenue at Rs. 527.37 Cr

Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24


Lupin Q3 FY25 profit up 40% at Rs. 855 Cr
News | February 14, 2025

Lupin Q3 FY25 profit up 40% at Rs. 855 Cr

Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore